Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2026 11:58 ET | Source: Mulvihill Canadian Bank Enhanced Yield ETF

Mulvihill Canadian Bank Enhanced Yield ETF Announces Year End Results

TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net...
March 28, 2026 11:55 ET | Source: Kessler Topaz Meltzer & Check LLP

GDDY Investigation: Kessler Topaz Meltzer & Check, LLP Encourages GoDaddy Inc. (NYSE: GDDY) Investors to Contact the Firm

RADNOR, Pa., March 28, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) a nationally recognized securities litigation law firm, is investigating potential violations of...
March 28, 2026 11:45 ET | Source: Robbins Geller Rudman & Dowd LLP

SMCI INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Super Micro Computer, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Case alleges defendants failed to disclose Super Micro sales of servers were to companies based in China, in violation of U.S. export control laws.
March 28, 2026 11:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute

AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE,...
March 28, 2026 11:00 ET | Source: Sanofi Winthrop Industrie

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...
March 28, 2026 11:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...
March 28, 2026 11:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at 2026 AAD
March 28, 2026 10:34 ET | Source: CODE27

CODE27 Secures Over $10 Million in Funding to Build Immersive Interactive Character Companion Hardware

CODE27 Secures Over $10 Million in Funding to Build Immersive Interactive Character Companion Hardware
March 28, 2026 09:26 ET | Source: The Rosen Law Firm PA

領先的訴訟法律顧問 ROSEN 鼓勵 Trip.com Group Limited 的投資者在該所對 TCOM 提出證券集體訴訟的重要截止日期前聘請律師

紐約, March 28, 2026 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒在 2024 年 4 月 30 日至 2026 年 1 月 13 日（包括首尾兩日，簡稱「集體訴訟期」）期間購買了 Trip.com Group Limited 證券（NASDAQ:...
March 28, 2026 09:25 ET | Source: The Rosen Law Firm PA

ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara...